These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29685722)

  • 1. Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?
    Ancedy Y; Berthelot E; Lang S; Ederhy S; Boyer-Chatenet L; Di Angelantonio E; Soulat-Dufour L; Etienney A; Adavane-Scheublé S; Boccara F; Cohen A
    Arch Cardiovasc Dis; 2018 May; 111(5):357-369. PubMed ID: 29685722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
    Krishnamoorthy S; Khoo CW; Lim HS; Lane DA; Pignatelli P; Basili S; Violi F; Lip GY
    Eur J Clin Invest; 2013 Oct; 43(10):1032-8. PubMed ID: 23961715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
    Conway DS; Pearce LA; Chin BS; Hart RG; Lip GY
    Circulation; 2003 Jul; 107(25):3141-5. PubMed ID: 12796127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke.
    Yip HK; Lai SL; Lan MY; Chang WN; Liu JS; Kao YF; Chang YY; Lu CH; Chen WH; Lin HH; Liou CW
    Circ J; 2007 Mar; 71(3):321-6. PubMed ID: 17322628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between left atrial spontaneous echocardiographic contrast and 5-year stroke/death in patients with non-valvular atrial fibrillation.
    Soulat-Dufour L; Lang S; Etienney A; Ederhy S; Ancedy Y; Adavane S; Chauvet-Droit M; Nhan P; Di Angelantonio E; Boccara F; Cohen A
    Arch Cardiovasc Dis; 2020; 113(8-9):525-533. PubMed ID: 32873521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
    Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
    Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
    Roldán V; Marín F; Muiña B; Torregrosa JM; Hernández-Romero D; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2011 Jun; 57(25):2496-504. PubMed ID: 21497043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of atrial fibrillation duration on plasma von Willebrand factor level.
    Wysokinski WE; Cohoon KP; Konik EA; Melduni RM; Ammash NM; Asirvatham SJ; McBane RD
    Eur J Haematol; 2017 Dec; 99(6):569-576. PubMed ID: 28952167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery.
    Hernández-Romero D; Lahoz Á; Roldan V; Jover E; Romero-Aniorte AI; Martinez CM; Jara-Rubio R; Arribas JM; Garcia-Alberola A; Cánovas S; Valdés M; Marín F
    Europace; 2016 Sep; 18(9):1328-34. PubMed ID: 26566941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
    Lip GY; Pearce LA; Chin BS; Conway DS; Hart RG
    Heart; 2005 Jun; 91(6):759-63. PubMed ID: 15894770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.
    Ehrlich JR; Kaluzny M; Baumann S; Lehmann R; Hohnloser SH
    Clin Res Cardiol; 2011 Nov; 100(11):1029-36. PubMed ID: 21725858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.
    Conway DS; Pearce LA; Chin BS; Hart RG; Lip GY
    Circulation; 2002 Oct; 106(15):1962-7. PubMed ID: 12370220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
    Lip GY; Lowe GD; Rumley A; Dunn FG
    Br Heart J; 1995 Jun; 73(6):527-33. PubMed ID: 7626351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of von Willebrand factor for patients with atrial fibrillation: a meta-analysis of prospective cohort studies.
    Ye YZ; Chang YF; Wang BZ; Ma YT; Ma X
    Postgrad Med J; 2020 May; 96(1135):267-276. PubMed ID: 31771966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation.
    Zhang F; Yang XC; Jia XW; Tang XH; Wang Z; Wang ZQ
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4907-4912. PubMed ID: 29164570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.
    Siller-Matula J; Lang IM; Schoergenhofer C; Roest M; Jilma B
    Thromb Haemost; 2017 Aug; 117(9):1730-1738. PubMed ID: 28726980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Risks of Ischemic Stroke in Atrial Flutter versus Atrial Fibrillation.
    Al-Kawaz M; Omran SS; Parikh NS; Elkind MSV; Soliman EZ; Kamel H
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):839-844. PubMed ID: 29223550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation.
    Lip GY; Lane D; Van Walraven C; Hart RG
    Stroke; 2006 Sep; 37(9):2294-300. PubMed ID: 16888271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.